Sorafenib

For research use only. Not for use in humans.

目录号:S7397 别名: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。

规格 价格 库存 购买数量  
RMB 1205.41 现货
RMB 2214.52 现货
RMB 5503.41 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Sorafenib发表文献206篇:

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。
靶点
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外研究

Sorafenib抑制野生型和V599E突变型B-Raf活性,IC50分别为22 nM 和 38 nM。Sorafenib也能有效抑制mVEGFR2 (Flk-1),mVEGFR3,mPDGFRβ,Flt3,和c-Kit,IC50分别为15 nM,20 nM,57 nM,58 nM,和68 nM。Sorafenib 能够较弱地抑制FGFR-1,IC50 为580 nM。Sorafenib对ERK-1,MEK-1,EGFR,HER-2,IGFR-1,c-Met,PKB,PKA,cdk1/cyclinB,PKCα,PKCγ,和pim-1没有活性。Sorafenib显著抑制NIH 3T3细胞中VEGFR2磷酸化,IC50 为 30 nM,也会抑制HEK-293细胞中Flt-3磷酸化,IC50 为20 nM。Sorafenib有效阻断大多数细胞中MEK 1/2 和 ERK 1/2磷酸化,但不阻断A549 或 H460细胞中该过程,同时不影响PKB通路的抑制。Sorafenib抑制HAoSMC 和 MDA-MB-231细胞的增殖,IC50分别为0.28 μM 和 2.6 μM。[1]除了抑制RAF/MEK/ERK信号通路,Sorafenib tosylate显著抑制eIF4E的磷酸化作用,并以MEK/ERK依赖的方式下调肝癌(HCC)细胞中Mcl-1水平。Sorafenib 抑制PLC/PRF/5 和HepG2细胞的增殖,IC50分别为6.3 μM 和 4.5 μM,并诱导显著的细胞凋亡。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NGHBPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vDXWlEPTB;MD6wNFAxODNyMzFOwG0> NWLqSpVvW0GQR1XS
MONO-MAC-6 M{W4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jvXmlEPTB;MD6wNFQyQCEQvF2= NUj5SY1mW0GQR1XS
ALL-PO NX3sZ5lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDKTWM2OD1yLkCzNVg1KM7:TR?= M2e0fXNCVkeHUh?=
NKM-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7yd21oUUN3ME2wMlA4PDF4IN88US=> NF3yfJJUSU6JRWK=
CGTH-W-1 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;xWldZUUN3ME2wMlI2ODJ{IN88US=> NXvHb2dbW0GQR1XS
BB65-RCC NGjzTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfQXZFKSzVyPUCuOFcxPzNizszN NEXzZ|VUSU6JRWK=
NOS-1 M4PsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX5RWNJUUN3ME2wMlU3OzZizszN M2O2enNCVkeHUh?=
SH-4 M4WwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfrTYdiUUN3ME2wMlY2PjF|IN88US=> NVnYOGdEW0GQR1XS
HOP-62 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjNeI1KSzVyPUCuPFUxQDhizszN MUPTRW5ITVJ?
HCC2998 NWDJW4dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwOEi4NVgh|ryP MV7TRW5ITVJ?
GDM-1 NGnXUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHQTWM2OD1yLkmwOlk5KM7:TR?= MkLLV2FPT0WU
KM12 M{jpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPvb|RKSzVyPUGuNFIxQThizszN NX;Tc4IxW0GQR1XS
LB2518-MEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwMkC4NFkh|ryP M375NXNCVkeHUh?=
NCI-H1436 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nINmlEPTB;MT6yNVY4QCEQvF2= NWfHOXhJW0GQR1XS
EM-2 M321Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwM{W1O|gh|ryP MX\TRW5ITVJ?
LAMA-84 M3naWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvNSFRKSzVyPUGuN|c3PDhizszN M{T2dXNCVkeHUh?=
KG-1 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O4fGlEPTB;MT60O|k{PSEQvF2= NXfNOWNTW0GQR1XS
A388 Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vFU2lEPTB;MT61PVE3PSEQvF2= MnrVV2FPT0WU
no-10 NIPPW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX0b5hKSzVyPUGuOlE4OjZizszN NIXieGtUSU6JRWK=
SF126 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLlTWM2OD1zLk[zPFEzKM7:TR?= NV7pOIN2W0GQR1XS
MEG-01 NHfOTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXLWnhKSzVyPUGuPFA6QCEQvF2= NXi0XlZvW0GQR1XS
A3-KAW M133SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFwOEi0NkDPxE1? MVHTRW5ITVJ?
D-247MG NFPuPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTR[Zc1UUN3ME2yMlE1PDhizszN M4\LWnNCVkeHUh?=
OVCAR-4 NHXZfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nId2lEPTB;Mj6yNVM6OyEQvF2= NVvFZ3hqW0GQR1XS
NCI-SNU-1 NUDYV|ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e2RmlEPTB;Mj6zNVYzKM7:TR?= MX3TRW5ITVJ?
NCI-H2171 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJwM{m3OlQh|ryP NX;5eHpEW0GQR1XS
SIG-M5 M2jCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJwNEKyOFIh|ryP NFTCO2pUSU6JRWK=
BE-13 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TvWmlEPTB;Mj62PVYxQSEQvF2= NIDDfHlUSU6JRWK=
K052 NGL0NFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnPUnp6UUN3ME2yMlc1PjF4IN88US=> NYrIUVVCW0GQR1XS
L-540 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\qcmlEPTB;Mj63OVc5QSEQvF2= NV7FOY1rW0GQR1XS
KMOE-2 NVLXRm1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTkOXVKSzVyPUKuPFE{PSEQvF2= Mm\UV2FPT0WU
MFH-ino MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXBTWM2OD1{LkmyNVg2KM7:TR?= M33kU3NCVkeHUh?=
HL-60 NXL1TGo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTTTWM2OD1|LkC2Nlk6KM7:TR?= M2C0XXNCVkeHUh?=
HCC2218 NVXVT4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LmeGlEPTB;Mz6xNlAxOyEQvF2= NYDGbpEzW0GQR1XS
TE-5 NFXFSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfiVZNKSzVyPUOuNVMyPjJizszN MVzTRW5ITVJ?
MZ1-PC M2jUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\Y[3drUUN3ME2zMlQ4PTB7IN88US=> M2DTbHNCVkeHUh?=
MRK-nu-1 NIX5NINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;qWJNjUUN3ME2zMlYyPDZ6IN88US=> NIS3V|ZUSU6JRWK=
MZ7-mel M1\Eemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnENFNKSzVyPUOuOlYxQTlizszN M2HIO3NCVkeHUh?=
BC-1 Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomzTWM2OD1|Lke0NFIh|ryP M2XrbnNCVkeHUh?=
ST486 MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTNwOEO2O|Mh|ryP NV;qeI5kW0GQR1XS
KS-1 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwOEixPVgh|ryP Mlj2V2FPT0WU
SK-NEP-1 Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwMU[4NVUh|ryP NY[1VoRLW0GQR1XS
BC-3 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DCV2lEPTB;ND6yN|M6OSEQvF2= MUDTRW5ITVJ?
NCI-H1581 M{PDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPGTWM2OD12LkK4O|k5KM7:TR?= Mn\JV2FPT0WU
MHH-PREB-1 NXjySGdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHXTWM2OD12LkSwOFg1KM7:TR?= M4e5dXNCVkeHUh?=
NOMO-1 M{D1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKzTWM2OD12LkS4PVA2KM7:TR?= NUn0R3VFW0GQR1XS
QIMR-WIL NWTmV3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;JbWlEPTB;NT6wO|I6PCEQvF2= MYDTRW5ITVJ?
SF539 NFu3U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL6dJhqUUN3ME21MlE{OjJ5IN88US=> MlL3V2FPT0WU
TE-12 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTVwMkS5Nlkh|ryP MkfRV2FPT0WU
NCI-H510A MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTVwNEG2PFUh|ryP M2DNOHNCVkeHUh?=
JAR NU\IbFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTVwNUC4NlQh|ryP MVXTRW5ITVJ?
no-11 M4PvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTVwN{O1Olgh|ryP NX;sdXVrW0GQR1XS
BV-173 NV24RY5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPNTWM2OD13Lkm1OlgzKM7:TR?= M4PRPHNCVkeHUh?=
SR MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rTNmlEPTB;Nj6wNFY4QCEQvF2= M3;aVXNCVkeHUh?=
MOLT-16 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36xO2lEPTB;Nj6yOVI3PiEQvF2= NH7oUVhUSU6JRWK=
MZ2-MEL Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXUTWM2OD14LkOxPFM6KM7:TR?= NULRSHR1W0GQR1XS
SW954 NE\SRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PJc2lEPTB;Nj60OVg3PiEQvF2= NGS3b4pUSU6JRWK=
ML-2 NWXrbllvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zXcGlEPTB;Nj61Nlg1QSEQvF2= NHvmd3NUSU6JRWK=
OCI-AML2 NHHEUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSyTWM2OD14Lk[xNFYzKM7:TR?= MXzTRW5ITVJ?
SIMA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXeyRXNvUUN3ME23MlAxOTBzIN88US=> MnezV2FPT0WU
DOHH-2 NFjjSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPW2lEPTB;Nz6wOVY4PiEQvF2= NFjpdZdUSU6JRWK=
697 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTdwMEW5PFkh|ryP NEHOUZRUSU6JRWK=
NB1 M1nsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:2XmlEPTB;Nz60NFQxPyEQvF2= NYfJZodMW0GQR1XS
D-392MG NHryT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H6fGlEPTB;Nz62NlY3OyEQvF2= NWHiPGRHW0GQR1XS
ES8 NHHz[|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLCbZdrUUN3ME23Mlc3PTB|IN88US=> MVzTRW5ITVJ?
RPMI-8226 M1n1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHWVVZKSzVyPUeuPFQ2OTFizszN NXizeGRIW0GQR1XS
IST-MEL1 M3n6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPjVok1UUN3ME24MlQxODB{IN88US=> NXXo[ZJOW0GQR1XS
NB14 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTEfHpjUUN3ME24MlY{OTN|IN88US=> M4e1cHNCVkeHUh?=
HD-MY-Z MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRThwNkO3OFYh|ryP MW\TRW5ITVJ?
TE-10 MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT4OplKSzVyPUiuO|Y{PTNizszN NVflTml1W0GQR1XS
LC-1F NFXpcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2wcmtKSzVyPUmuNVA5OzRizszN NGX4[XNUSU6JRWK=
OS-RC-2 M3[xVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDXTWVjUUN3ME25MlEyOjR|IN88US=> M2nsUnNCVkeHUh?=
NCI-SNU-16 NYOweYhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDaTWM2OD17LkKxNFI3KM7:TR?= NYK2[JU6W0GQR1XS
SHP-77 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT5eYhoUUN3ME25MlcyPjZ{IN88US=> NWDzUVlMW0GQR1XS
A4-Fuk MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj0VGFrUUN3ME25Mlc2PjFizszN M4PRNnNCVkeHUh?=
NB6 M3GzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTlwN{[wNlkh|ryP NUK0eXJ5W0GQR1XS
JiyoyeP-2003 NXPwc2RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFyLkS3OFUh|ryP NU\lWZhmW0GQR1XS
DMS-114 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTuTWM2OD1zMD61OFQyKM7:TR?= NFPmXmZUSU6JRWK=
NB7 NFGzdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jNW2lEPTB;MUCuO|UzPiEQvF2= NWr0[XNLW0GQR1XS
NCI-H747 NVLaN3pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3IS5dKSzVyPUGxMlEzOTZizszN MWjTRW5ITVJ?
HH NIfEXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WxN2lEPTB;MUGuN|g4PiEQvF2= MnzlV2FPT0WU
EW-18 NILhboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPBTWM2OD1zMT65NFQ1KM7:TR?= NH7wV4pUSU6JRWK=
CHP-126 MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFzLkm3N|gh|ryP MmHUV2FPT0WU
NTERA-S-cl-D1 M1PpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrzTIdKSzVyPUGyMlAzPzhizszN MVHTRW5ITVJ?
DEL NGj6TFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\pTWM2OD1zMj6wPVg2KM7:TR?= NWrJUIFuW0GQR1XS
LU-139 NVjnWGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;QSGlEPTB;MUKuOVQyOyEQvF2= M{fYcXNCVkeHUh?=
P30-OHK M2X1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jmXWlEPTB;MUKuOVQ4QSEQvF2= M2L4eHNCVkeHUh?=
NCI-H1522 NXX4U3FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnYTWM2OD1zMj63OFYh|ryP MVTTRW5ITVJ?
NCI-H1299 NGm0c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF|LkK5NVEh|ryP MmTVV2FPT0WU
UACC-257 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnLTWM2OD1zMz61NVI3KM7:TR?= MWjTRW5ITVJ?
Calu-6 NUL6NoRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DlOWlEPTB;MUOuOlA1PiEQvF2= Mk\FV2FPT0WU
NCI-H1882 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13zNmlEPTB;MUOuPFU2PSEQvF2= MUHTRW5ITVJ?
BB30-HNC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV75bnNuUUN3ME2xOE4xPjB7IN88US=> NH3nfZJUSU6JRWK=
ES1 M{frd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF2LkG1OVEh|ryP MUXTRW5ITVJ?
NCI-H1694 M1vpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvoTWM2OD1zND60PFEyKM7:TR?= NUjFe3R[W0GQR1XS
IST-SL1 NVvkfG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVmzd3BJUUN3ME2xOE46PjF4IN88US=> MVXTRW5ITVJ?
ECC4 M3f1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF3LkC1OVgh|ryP NEjo[GFUSU6JRWK=
MDA-MB-134-VI NEnocmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELUTWRKSzVyPUG1MlQyOzFizszN MUjTRW5ITVJ?
SCH MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq5TWM2OD1zNT60O|I5KM7:TR?= MmXTV2FPT0WU
SK-N-FI NULlcVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrlOJlZUUN3ME2xOU43PTN2IN88US=> M4\qcnNCVkeHUh?=
HDLM-2 NXz1RlhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF4LkC3NVQh|ryP M3fpVHNCVkeHUh?=
Ramos-2G6-4C10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;ySGlEPTB;MU[uNVI6PyEQvF2= NVjEW|Z4W0GQR1XS
EW-24 NV;3UVZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPTfnF1UUN3ME2xOk4yPjZzIN88US=> NIP4S2NUSU6JRWK=
NCI-H2141 NHW0S5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvTTWM2OD1zNj6xPFkh|ryP NFPlepFUSU6JRWK=
LC4-1 M4q2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF4Lk[xNVkh|ryP M2rTdHNCVkeHUh?=
HT-144 NXTxNlhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF5LkCwOkDPxE1? NHfpXYdUSU6JRWK=
SK-MEL-1 M3rKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;SdldNUUN3ME2xO{4xODd{IN88US=> NHG0UFZUSU6JRWK=
SCC-15 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HOeWlEPTB;MUeuNVY{QCEQvF2= NGfhfoVUSU6JRWK=
C8166 M1X4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfJb5VKSzVyPUG3MlY5OzNizszN M3fNTnNCVkeHUh?=
GOTO M2D4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF5LkizOFQh|ryP Mk\GV2FPT0WU
COR-L279 NHG2OXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnjTWM2OD1zOD6xN|YzKM7:TR?= NEfFOWNUSU6JRWK=
K-562 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF6LkexOFMh|ryP MnfVV2FPT0WU
ES3 NEfMfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL2SJRKSzVyPUG4MlgxPDFizszN MUfTRW5ITVJ?
LU-165 M2HyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHJR3BvUUN3ME2xPU44ODB6IN88US=> NX7Rcpd7W0GQR1XS
KM-H2 M2DEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETzOGJKSzVyPUKwMlMyQDRizszN MlzzV2FPT0WU
RL MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJyLkm2PVIh|ryP Mki3V2FPT0WU
EW-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3tXW5UUUN3ME2yNU4yQDh7IN88US=> NYXvXoNuW0GQR1XS
A101D NYTBV405T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJzLkO3OVIh|ryP MUXTRW5ITVJ?
HUTU-80 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjlTWM2OD1{MT6zPVQ3KM7:TR?= MWXTRW5ITVJ?
NCI-H23 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzSXplKSzVyPUKxMlM6QTJizszN NYLabXc6W0GQR1XS
PF-382 NYfpNWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjHW|BKSzVyPUKxMlQ1ODNizszN M{DGVHNCVkeHUh?=
LB373-MEL-D NHT5eoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjEdphKSzVyPUKxMlU3OTVizszN MmnRV2FPT0WU
TE-8 NVKwXGppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz4O5pKSzVyPUKxMlY{QTRizszN MXHTRW5ITVJ?
TE-9 NUjVbYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HSdWlEPTB;MkGuPFUyOyEQvF2= NEH6UlNUSU6JRWK=
Daudi NUL3PXNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTxe3d5UUN3ME2yNU46OzB2IN88US=> MljuV2FPT0WU
D-542MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHGTWM2OD1{Mj6wNlU3KM7:TR?= M{jHbXNCVkeHUh?=
U-698-M Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfVZW5KSzVyPUKyMlQ3ODNizszN MkfmV2FPT0WU
ES6 M4n0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS5TWM2OD1{Mj63N|Y3KM7:TR?= Mmr0V2FPT0WU
DU-4475 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ|Lki4PVch|ryP MnO4V2FPT0WU
ECC12 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHmTWM2OD1{ND6yPFA{KM7:TR?= MWHTRW5ITVJ?
C2BBe1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ2LkOyN|kh|ryP MnfTV2FPT0WU
IST-SL2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXVcItKSzVyPUK0MlQ{PjJizszN NVzHVGd3W0GQR1XS
DJM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe2NotKSzVyPUK0MlUzOjFizszN NFHWW2RUSU6JRWK=
DMS-153 NULJfVlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ2Lki2NVQh|ryP Ml7mV2FPT0WU
NB13 NInjVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXaZlgyUUN3ME2yOU4xOjZ3IN88US=> NFvXRW5USU6JRWK=
SK-N-DZ NHjrb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjEWWhKSzVyPUK2MlM1OTRizszN MoPuV2FPT0WU
COR-L88 NITFOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v1fmlEPTB;Mk[uOVc6PiEQvF2= NGXlcHZUSU6JRWK=
LU-65 NXv2OYhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ4Lki1N|Uh|ryP M3r6OXNCVkeHUh?=
TGBC1TKB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n1e2lEPTB;Mk[uPVgzQCEQvF2= MUTTRW5ITVJ?
THP-1 NGrpNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTkR3ZlUUN3ME2yO{4zOTRzIN88US=> NUO0O5hmW0GQR1XS
ONS-76 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13TUmlEPTB;MkeuN|MzKM7:TR?= M1rmRXNCVkeHUh?=
LC-2-ad NETwRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ5Lk[yN|Eh|ryP MXPTRW5ITVJ?
EW-13 NY\4OJBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTkcoJKSzVyPUK5MlE4PDZizszN NF;lUotUSU6JRWK=
MS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjsc4ZnUUN3ME2zNE44Ojd6IN88US=> MXrTRW5ITVJ?
NCI-H2227 NGjrdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fHZ2lEPTB;M{CuPVgxPiEQvF2= NGizRWdUSU6JRWK=
LXF-289 M1y5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNzLkS0PVIh|ryP MmfnV2FPT0WU
MC116 NVvPd4NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\Sd4FtUUN3ME2zNk4xQDJ4IN88US=> Mnn1V2FPT0WU
EVSA-T MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPTVnZiUUN3ME2zNk4zPTh3IN88US=> MWfTRW5ITVJ?
CTB-1 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\ZU3dKSzVyPUOzMlEyODFizszN MYjTRW5ITVJ?
COLO-320-HSR NVvLcXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTN|LkG2NFMh|ryP NIHUdXNUSU6JRWK=
NCI-H2196 NVnKSHZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLQTZRKSzVyPUOzMlI2PTdizszN M2KzVXNCVkeHUh?=
LB2241-RCC NYPMTnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrqTWM2OD1|Mz6zNVM2KM7:TR?= NXK0SJF4W0GQR1XS
LS-513 MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\L[XdKSzVyPUOzMlg3OzhizszN NWj3SYE6W0GQR1XS
LP-1 NGW4d2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XwNWlEPTB;M{OuPVk2PiEQvF2= M{DyfHNCVkeHUh?=
A253 NXHLV2JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3TZm9KSzVyPUO0MlIzQTZizszN MkD1V2FPT0WU
SK-MM-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPkR3dKSzVyPUO0Mlk1PTFizszN Ml;OV2FPT0WU
NCI-H1963 NGfOVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\oTWM2OD1|NT6zNFczKM7:TR?= MVrTRW5ITVJ?
MMAC-SF M1;LZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPjbIFoUUN3ME2zOU45Pzh3IN88US=> NHXBVYRUSU6JRWK=
LB831-BLC NX7zNVJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P4VWlEPTB;M{[uNFY2PCEQvF2= NYPpPZNMW0GQR1XS
WSU-NHL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j4PWlEPTB;M{[uNVY1KM7:TR?= NGHxXWNUSU6JRWK=
CESS NY\WeldIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HHemlEPTB;M{[uNlg1QCEQvF2= NIr2TGVUSU6JRWK=
NEC8 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN4LkW4N|Uh|ryP NXHXdlhSW0GQR1XS
KNS-42 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTN5LkGyN|ch|ryP M2Gxe3NCVkeHUh?=
MHH-CALL-2 NF\IV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i5PGlEPTB;M{euNVgzOSEQvF2= M1G5[nNCVkeHUh?=
K5 NFPGUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\jfJhKSzVyPUO4MlQ{KM7:TR?= MoDOV2FPT0WU
CP66-MEL NFLk[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN7LkC3N|Mh|ryP M4q4NHNCVkeHUh?=
OPM-2 MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW5TWM2OD1|OT64OFMzKM7:TR?= M37uNHNCVkeHUh?=
IST-MES1 M{HBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\WdmlEPTB;NECuN|A6PiEQvF2= NEX2RodUSU6JRWK=
EC-GI-10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nUU2lEPTB;NEGuOVgxPSEQvF2= MlzUV2FPT0WU
CTV-1 NXjOelNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXewcGxCUUN3ME20Nk45PDB4IN88US=> NFjubXlUSU6JRWK=
DG-75 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHUcJhVUUN3ME20N{44PTl3IN88US=> NYe4elRjW0GQR1XS
KNS-81-FD NUe0c5JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTR3LkSwOVgh|ryP NHLYW2hUSU6JRWK=
NCI-H82 NHPwW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHTRVFKSzVyPUS1MlU4PThizszN Mli1V2FPT0WU
RPMI-8866 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPCNI5KSzVyPUS2MlE5PzNizszN Mn;YV2FPT0WU
ACN MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M325cGlEPTB;NE[uOFM1KM7:TR?= NWTONXpEW0GQR1XS
NCI-H1395 NX[1bYo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTrU5pKSzVyPUS2MlQ4PTZizszN NX74XnVLW0GQR1XS
NCI-H209 NUOwUpB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnK[4VKSzVyPUS3MlE1ODVizszN Mn30V2FPT0WU
TGW NUTiZpZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\tOXR6UUN3ME20PU4xPzlzIN88US=> MkjhV2FPT0WU
NCI-H748 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTR7LkS3OVMh|ryP M4nLZXNCVkeHUh?=
EKVX MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33xOGlEPTB;NEmuOlYzQCEQvF2= Mkn3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
体内研究 Sorafenib(~60 mg/kg)口服给药,对各种人肿瘤异种移植模型,包括MDA-MB-231,Colo-205,HT-29,DLD-1,NCI-H460,和A549表现出广谱的、剂量依赖性抗肿瘤活性,而没有毒性。与抗肿瘤功效相联系,Sorafenib 治疗有效抑制HT-29 和 MDA-MB-231异种移植物中MEK 1/2磷酸化和pERK 1/2水平,但对Colo-205异种移植物没有作用,并且也能显著抑制MDA MB-231,HT-29 和 Colo-205肿瘤异种移植物中肿瘤微血管面积(MVA)和微血管密度(MVD)。[1] 在SCID小鼠体内,Sorafenib治疗对PLC/PRF/5肿瘤异种移植产生剂量依赖性生长抑制,10 mg/kg和30 mg/kg剂量下,TGIs分别为49%和78%,与ERK 和 eIF4E磷酸化抑制,微血管面积减少,和肿瘤细胞凋亡的诱导相一致。[2] Sorafenib通过下调NF-κB介导的Mcl-1 和 cIAP2表达的作用机制使bax-/-细胞对TRAIL剂量依赖性敏感。 Sorafenib (30-60 mg/kg) 与 TRAIL (5 mg/kg)结合对TRAIL抗性HCT116 bax-/-和HT29肿瘤异种移植物表现出显著的功效。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

生化检测:

重组杆状病毒表达的Raf-1 (残基305–648)和 B-Raf (残基 409–765)以融合蛋白纯化。全长人MEK-1由PCR产生,并以大肠杆菌裂解物中的融合蛋白纯化。将Sorafenib加入到含Raf-1 (80纳克),或B-Raf (80 纳克) 以及MEK-1 (1 微克) 混合物的实验缓冲液[20 mM Tris (pH 8.2),100 mM NaCl,5 mM MgCl2,和0.15% β-巯基乙醇]中,DMSO终浓度为1%。加入25微升10 μM γ[33P]ATP (400 Ci/mol)启动Raf激酶试验(终体积50微升),并在32 °C下培育25分钟。磷酸化的MEK-1通过过滤到磷酸纤维素板上采集,使用1%磷酸洗掉未结合的放射性。微波炉加热干燥后,使用β型板计数器量化过滤器结合放射性。人VEGFR2 (KDR)激酶域被表达,并从Sf9裂解物中纯化。VEGFR2的时间分辨荧光分析法能量转移测试在96孔不透明板中以时间分辨荧光分析法能量转移格式进行。最终反应条件如下:1 到10 μM ATP,25 nM poly GT生物素,2 nM 铕标记的磷酸(p)-酪氨酸抗体(PY20),10 nM APC,1% DMSO 终浓度的1 到 7 nM 细胞质激酶域,50 mM HEPES (pH 7.5),10 mM MgCl2,0.1 mM EDTA,0.015% Brij-35,0.1 毫克/毫升BSA,和0.1% β-巯基乙醇。反应体积为100微升,加入酶启动反应。反应启动~1.5 到 2.0小时后,板以615 和 665 nM在Perkin-Elmer VictorV多标记分析仪上读数。信号按如下比率计算:对每孔(665 nm/615 nM) × 10,000。对IC50的产生,在酶起始反应之前加入Sorafenib。50倍的库存板由Sorafenib在50% DMSO/50%蒸馏水溶液中连续稀释制得。最终Sorafenib在1% DMSO中的浓度范围为10 μM 到 4.56 nM。
细胞实验:[1]
- 合并
  • Cell lines: MDA-MB-231,和 HAoSMC
  • Concentrations: 溶解于DMSO,终浓度为~10 μM
  • Incubation Time: 72小时
  • Method: 细胞在逐渐增加浓度的Sorafenib下暴露72小时。细胞数通过Cell TiterGlo ATP发光测定试剂盒进行定量。该试验通过测定基于细胞中ATP量的发光信号,测量每孔中的活细胞。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 雌性 NCr-nu/nu 小鼠,皮下植入MDA-MB-231,Colo-205,HT-29,H460,或 A549 细胞
  • Formulation: 以4倍(4 ×储备溶液,稀释为1 ×)溶解于聚氧乙烯蓖麻油/乙醇(50:50)
  • Dosages: ~60 mg/kg
  • Administration: 口服,每天一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+45% PEG 400+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 464.82
化学式

C21H16ClF3N4O3

CAS号 284461-73-0
储存条件 粉状
溶于溶剂
别名 BAY 43-9006

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000737 Not yet recruiting Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib Advanced Hepatocellular Carcinoma Yiviva Inc. August 15 2019 Phase 2
NCT03958669 Not yet recruiting -- Hepatocellular Carcinoma|Sorafenib University Hospital Tuebingen|German Federal Ministry of Education and Research July 1 2019 --
NCT03764293 Not yet recruiting Drug: SHR-1210|Drug: Apatinib|Drug: Sorafenib Locally Advanced or Metastatic and Unresectable HCC Jiangsu HengRui Medicine Co. Ltd. January 2019 Phase 3
NCT03582618 Recruiting Drug: Sorafenib|Drug: CVM-1118 Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Raf Signaling Pathway Map

相关Raf产品

Tags: 购买Sorafenib | Sorafenib供应商 | 采购Sorafenib | Sorafenib价格 | Sorafenib生产 | 订购Sorafenib | Sorafenib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID